Skip to main content

John Kane, MD

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...
03/01/2019
Goal: To assess physicians’ practice patterns in recognition, management, and knowledge of emerging treatments for treatment-resistant schizophrenia (TRS). Methods: •    A 26-question a...
03/01/2019
Background: Patients with tardive dyskinesia (TD) often take multiple concomitant medications for psychiatric comorbidities. Data from long-term valbenazine trials were analyzed to evalua...
03/01/2019